Please assess the completion status of the following clinical trial:

Trial Title: Combination Chemotherapy Plus Radiation Therapy Followed by Surgery in Treating Patients With Stage IIIB Non-Small Cell Lung Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically or cytologically confirmed primary stage IIIB non-small cell lung cancer (NSCLC)~  * T4, any N, M0 or any T, N3, M0~ * No N3 disease due to scalene or supraclavicular lymph node involvement~* No primary tumors located in the lower lobe combined with contralateral upper higher mediastinal lymph node involvement~* No mixed tumor types with small cell lung cancer~* At least 1 unidimensionally measurable target lesion~  * At least 20 mm by conventional techniques OR~ * At least 10 mm by spiral CT scan~* No pre-existing pleural or pericardial effusion~* No CNS involvement by CT scan or MRI~PATIENT CHARACTERISTICS:~Age:~* 18 to 75~Performance status:~* WHO 0-1~Life expectancy:~* Not specified~Hematopoietic:~* Absolute neutrophil count at least 2,000/mm\^3~* Platelet count at least 100,000/mm \^3~Hepatic:~* Bilirubin no greater than 1.5 times upper limit of normal (ULN)~* AST/ALT no greater than 1.5 times ULN~* Alkaline phosphatase no greater than 2.5 times ULN~Renal:~* Creatinine no greater than 1.25 times ULN~* Creatinine clearance at least 60 mL/min~Cardiovascular:~* No clinical evidence of superior vena cava syndrome~Pulmonary:~* Postoperative FEV1 and KCO greater than 40% predicted~* VO2 max greater than 15 mL/min/kg (if postoperative KCO no greater than 40% predicted)~Other:~* No other primary malignancy except carcinoma in situ of the cervix, adequately treated basal cell skin cancer, or other malignancy treated more than 5 years ago without recurrence (excluding melanoma, breast cancer, or hypernephroma)~* No active uncontrolled infection requiring IV antibiotics~* No pre-existing sensory neurotoxicity grade 2 or greater~* No psychological, familial, sociological, or geographical condition that would preclude study compliance~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~PRIOR CONCURRENT THERAPY:~Biologic therapy:~* No prior immunotherapy for NSCLC~* No concurrent immunotherapy during induction chemoradiotherapy~* Concurrent colony stimulating factors allowed~Chemotherapy:~* No prior chemotherapy for NSCLC~Endocrine therapy:~* No concurrent anticancer hormonal agents (except corticosteroids for antiemetic prophylaxis) during induction chemoradiotherapy~Radiotherapy:~* No prior radiotherapy for NSCLC~Surgery:~* No prior surgery for NSCLC~Other:~* No other concurrent anticancer drugs during induction chemoradiotherapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).